"The rally following the deal highlights the incremental market opportunity and removal of the legal overhang for Hims & Hers shares. Beyond the deal itself, Barclays argues the market is still underappreciating Hims' opportunity from new products - a signal that the firm sees the stock's recent recovery as just the beginning of a re-rating, not the end of it."
"Under the new arrangement, Hims will distribute approved Ozempic and Wegovy injectables, as well as the oral Wegovy pill, at Novo's self-pay prices on its platform, while agreeing to stop advertising compounded GLP-1 drugs outside of clinically necessary cases. The FDA publicly endorsed the resolution, with commissioner Marty Makary calling the deal a win for access and affordability."
Barclays increased its price target on Hims & Hers Health to $29 from $25, maintaining an Overweight rating following the company's settlement with Novo Nordisk that eliminated significant legal uncertainty. The analyst views the deal as a dual catalyst, removing the legal overhang while revealing an underappreciated market opportunity in new products. Under the agreement, Hims will distribute approved Ozempic and Wegovy injectables and oral Wegovy at Novo's self-pay prices while ceasing compounded GLP-1 advertising outside clinical necessity. The FDA endorsed the resolution. Simultaneously, Canaccord trimmed Progyny's price target to $19 from $26 while maintaining a Hold rating, citing stable but uncertain business trends following Q4 results and cautious guidance for 2026.
#glp-1-drugs #healthcare-analyst-ratings #novo-nordisk-settlement #fertility-benefits #pharmaceutical-pricing
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]